First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
IICP is a registered charitable society working in the disability sector since 1974
CRL shall invest another Rs. 200 crore for creation of additional beds
She has held senior positions at Coca-Cola in China and PepsiCo in India
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Bloom has pioneered a technology to transform plant waste into valuable chemical products
Subscribe To Our Newsletter & Stay Updated
